At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Metastatic NSCLC enrolled in CRCHUM Lung Cancer Registry and PERa registry
- ✓Ability to provide written informed consent
- ✓ECOG performance status 0-3
- ✕Any lesion larger than 5cm
- ✕Pregnancy or breastfeeding
- ✕Medical condition precluding radiotherapy or preventing follow-up
- ✕Spinal cord compression
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04405401Phase 2RecruitingUpdate OverdueUpdated 30mo ago · Completion was 12mo agoStereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Non Small Cell Lung Cancer: A Registry-based Phase II Randomized Trial
In Brief
A Phase 2 clinical trial evaluating SABR and Standard of care for Lung Cancer Metastatic. Currently recruiting, targeting 68 participants across 1 site.
Signals
Detailed Summary
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Study Details
Timeline
Interventions
SABR to all oligoprogressive lesions + continuation of current systemic therapy
Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.